JP2020510075A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020510075A5 JP2020510075A5 JP2019550800A JP2019550800A JP2020510075A5 JP 2020510075 A5 JP2020510075 A5 JP 2020510075A5 JP 2019550800 A JP2019550800 A JP 2019550800A JP 2019550800 A JP2019550800 A JP 2019550800A JP 2020510075 A5 JP2020510075 A5 JP 2020510075A5
- Authority
- JP
- Japan
- Prior art keywords
- inhibitor
- pharmaceutically acceptable
- acceptable salt
- therapeutic agent
- erα
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762472345P | 2017-03-16 | 2017-03-16 | |
| US62/472,345 | 2017-03-16 | ||
| PCT/US2018/022961 WO2018170447A1 (en) | 2017-03-16 | 2018-03-16 | Combination therapies for the treatment of breast cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020510075A JP2020510075A (ja) | 2020-04-02 |
| JP2020510075A5 true JP2020510075A5 (https=) | 2021-04-30 |
| JP7219224B2 JP7219224B2 (ja) | 2023-02-07 |
Family
ID=61874039
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019550800A Active JP7219224B2 (ja) | 2017-03-16 | 2018-03-16 | 乳癌の治療のための組合せ療法 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US11083722B2 (https=) |
| EP (2) | EP4218820A3 (https=) |
| JP (1) | JP7219224B2 (https=) |
| KR (1) | KR102517650B1 (https=) |
| CN (1) | CN110636862B (https=) |
| AU (1) | AU2018234903B2 (https=) |
| BR (1) | BR112019019261A2 (https=) |
| CA (1) | CA3056701A1 (https=) |
| IL (1) | IL269357B2 (https=) |
| MA (1) | MA47776A (https=) |
| MX (1) | MX2019010981A (https=) |
| RU (1) | RU2764724C2 (https=) |
| SG (1) | SG11201908531WA (https=) |
| WO (1) | WO2018170447A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2747399C2 (ru) * | 2016-11-28 | 2021-05-04 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Соли производного индазола и их кристаллы |
| EP3738084A4 (en) | 2018-01-08 | 2021-11-17 | G1 Therapeutics, Inc. | SUPERIOR G1T38 DOSING SCHEMES |
| JP2023548340A (ja) * | 2020-11-06 | 2023-11-16 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 乳癌の治療方法 |
| CN113018357A (zh) * | 2021-02-08 | 2021-06-25 | 湖南农业大学 | 茶多酚和帕博西尼联合在制备治疗乳腺癌的制剂中的用途 |
| EP4626890A1 (en) | 2022-12-01 | 2025-10-08 | KRKA, d.d., Novo mesto | Ribociclib salts and formulations thereof |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6399633B1 (en) | 1999-02-01 | 2002-06-04 | Aventis Pharmaceuticals Inc. | Use of 4-H-1-benzopryan-4-one derivatives as inhibitors of smooth muscle cell proliferation |
| DE19959546A1 (de) | 1999-12-09 | 2001-06-21 | Rhone Poulenc Rorer Gmbh | Pharmazeutische Zubereitung zur Behandlung von Tumorerkrankungen |
| HUP0204126A3 (en) | 2000-01-18 | 2006-02-28 | Aventis Pharma Inc | Pseudopolymorph of (-)-cis-2-(2-chlorophenyl)-5,7-dihydroxy-8[4r-(3s-hydroxy-1-methyl)piperidinyl]-4h-1-benzopyran-4-one, process for their preparation and pharmaceutical compositions containing them |
| IL150643A0 (en) | 2000-01-18 | 2003-02-12 | Aventis Pharma Inc | Ethanol solvate of (-)-cis-2-(2-chlorophenyl)-5,7-dihydroxy-8 [4r-(3s-hydroxy-1-methyl) piperidinyl]-4h-1-benzopyran-4-one |
| US20050004007A1 (en) | 2000-09-12 | 2005-01-06 | Steven Grant | Promotion of adoptosis in cancer cells by co-administration of cyclin dependent kinase inhibitiors and cellular differentiation agents |
| MXPA04005939A (es) | 2002-01-22 | 2005-01-25 | Warner Lambert Co | 2-(piridin-2-ilamino)-pirido[2,3-d]pirimidin-7-onas. |
| CA2532965C (en) | 2003-07-22 | 2013-05-14 | Astex Therapeutics Limited | 3, 4-disubstituted 1h-pyrazole compounds and their use as cyclin dependent kinases (cdk) and glycogen synthase kinase-3 (gsk-3) modulators |
| WO2008007113A2 (en) | 2006-07-14 | 2008-01-17 | Astex Therapeutics Limited | Pharmaceutical combinations |
| AR054425A1 (es) | 2005-01-21 | 2007-06-27 | Astex Therapeutics Ltd | Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico. |
| MX2007008781A (es) | 2005-01-21 | 2007-09-11 | Astex Therapeutics Ltd | Compuestos farmaceuticos. |
| CN101146532B (zh) | 2005-01-21 | 2012-05-09 | 阿斯泰克斯治疗有限公司 | 药物化合物 |
| EP1845975A1 (en) | 2005-01-21 | 2007-10-24 | Astex Therapeutics Limited | Combinations of pyrazole kinase inhibitors and further antitumor agents |
| JP2008255008A (ja) | 2005-07-19 | 2008-10-23 | Tokyo Medical & Dental Univ | 滑膜細胞増殖抑制剤 |
| US7776832B2 (en) * | 2006-04-21 | 2010-08-17 | Gem Pharmaceuticals, Llc | Anticancer treatment with a combination of taxanes and 13-deoxyanthracyclines |
| TWI398252B (zh) | 2006-05-26 | 2013-06-11 | 諾華公司 | 吡咯并嘧啶化合物及其用途 |
| EP2043635A2 (en) | 2006-06-29 | 2009-04-08 | Astex Therapeutics Limited | Pharmaceutical combinations |
| EP2046330A2 (en) | 2006-07-14 | 2009-04-15 | Astex Therapeutics Limited | Pharmaceutical combinations |
| WO2008009954A1 (en) | 2006-07-21 | 2008-01-24 | Astex Therapeutics Limited | Medical use of cyclin dependent kinases inhibitors |
| US7902147B2 (en) | 2007-11-05 | 2011-03-08 | Duke University | Chronic lymphocytic leukemia prognosis and treatment |
| ES2522346T3 (es) | 2008-08-22 | 2014-11-14 | Novartis Ag | Compuestos de pirrolopirimidina como inhibidores de CDK |
| PA8852901A1 (es) | 2008-12-22 | 2010-07-27 | Lilly Co Eli | Inhibidores de proteina cinasa |
| UY33226A (es) | 2010-02-19 | 2011-09-30 | Novartis Ag | Compuestos de pirrolopirimidina deuterada como inhibidores de la cdk4/6 |
| EP2558092B1 (en) | 2010-04-13 | 2018-06-27 | Novartis AG | Combination comprising a cyclin dependent kinase 4 or cyclin dependent kinase 6 (cdk4/6) inhibitor and an mtor inhibitor for treating cancer |
| GB2483736B (en) * | 2010-09-16 | 2012-08-29 | Aragon Pharmaceuticals Inc | Estrogen receptor modulators and uses thereof |
| MX338327B (es) | 2010-10-25 | 2016-04-12 | G1 Therapeutics Inc | Inhibidores de cdk. |
| US20120115878A1 (en) | 2010-11-10 | 2012-05-10 | John Vincent Calienni | Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof |
| EP2937349B1 (en) | 2011-03-23 | 2016-12-28 | Amgen Inc. | Fused tricyclic dual inhibitors of cdk 4/6 and flt3 |
| EP2925365A1 (en) | 2012-11-28 | 2015-10-07 | Novartis AG | Combination therapy |
| ME03557B (me) | 2013-03-15 | 2020-07-20 | G1 Therapeutics Inc | Privremena zaštiтa normalnih ćelija током hemoterapije |
| CN105828822B (zh) | 2013-08-14 | 2019-10-18 | 诺华股份有限公司 | 用于治疗癌症的组合疗法 |
| WO2015136016A2 (en) | 2014-03-13 | 2015-09-17 | F. Hoffmann-La Roche Ag | Therapeutic combinations with estrogen receptor modulators |
| WO2016025650A1 (en) | 2014-08-13 | 2016-02-18 | Celgene Avilomics Research, Inc. | Combinations of an erk inhibitor and a cdk4/6 inhibitor and related methods |
| WO2016040848A1 (en) | 2014-09-12 | 2016-03-17 | G1 Therapeutics, Inc. | Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors |
| CN104529904B (zh) | 2015-01-09 | 2016-08-31 | 苏州明锐医药科技有限公司 | 玻玛西尼的制备方法 |
| WO2016126889A1 (en) | 2015-02-03 | 2016-08-11 | G1 Therapeutics, Inc. | Cdk4/6 inhibitor dosage formulations for the protection of hematopoietic stem and progenitor cells during chemotherapy |
| KR20250152679A (ko) * | 2015-04-29 | 2025-10-23 | 래디어스 파마슈티컬스, 인코포레이티드 | 암을 치료하는 방법 |
| MD3302471T2 (ro) * | 2015-05-29 | 2021-12-31 | Eisai R&D Man Co Ltd | Compuși de alchenă tetrasubstituiți și utilizarea acestora |
-
2018
- 2018-03-16 MX MX2019010981A patent/MX2019010981A/es unknown
- 2018-03-16 EP EP23159590.1A patent/EP4218820A3/en not_active Withdrawn
- 2018-03-16 SG SG11201908531W patent/SG11201908531WA/en unknown
- 2018-03-16 CN CN201880030008.9A patent/CN110636862B/zh active Active
- 2018-03-16 RU RU2019132893A patent/RU2764724C2/ru active
- 2018-03-16 MA MA047776A patent/MA47776A/fr unknown
- 2018-03-16 IL IL269357A patent/IL269357B2/en unknown
- 2018-03-16 EP EP18715441.4A patent/EP3595725B1/en active Active
- 2018-03-16 BR BR112019019261-1A patent/BR112019019261A2/pt not_active Application Discontinuation
- 2018-03-16 WO PCT/US2018/022961 patent/WO2018170447A1/en not_active Ceased
- 2018-03-16 KR KR1020197029851A patent/KR102517650B1/ko active Active
- 2018-03-16 CA CA3056701A patent/CA3056701A1/en active Pending
- 2018-03-16 JP JP2019550800A patent/JP7219224B2/ja active Active
- 2018-03-16 US US16/493,931 patent/US11083722B2/en active Active
- 2018-03-16 AU AU2018234903A patent/AU2018234903B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7330312B2 (ja) | Ｈｉｖを治療するためのトール様受容体の調節因子 | |
| JP2020510075A5 (https=) | ||
| RU2478387C2 (ru) | ИМИДАЗОХИНОЛИНЫ В КАЧЕСТВЕ ДВОЙНЫХ ИНГИБИТОРОВ ЛИПИДКИНАЗЫ И mTOR | |
| JP5547066B2 (ja) | 治療用組成物およびその使用 | |
| JP2021008516A (ja) | Ｈｉｖウイルス感染症の予防的または治療的処置に有用な治療用化合物 | |
| JP2017511360A5 (https=) | ||
| JP5769762B2 (ja) | 治療組成物およびその使用 | |
| CN104066706B (zh) | 炎症的治疗 | |
| JP2019511526A5 (https=) | ||
| JP2016521266A (ja) | イブルチニブ併用療法 | |
| RU2014141362A (ru) | Комбинированная терапия пролиферативных нарушений | |
| NO20065638L (no) | Formuleringer med kontrollert frigivelse inneholdende vardenafil | |
| KR20090013827A (ko) | Ｈｉｖ 환자에서 면역 재구성을 증진시키고 기회 감염을 치료하기 위한 ｃｃｒ５ 길항제 | |
| RU2600793C2 (ru) | Новый режим приема n-гидрокси-4-{2-[3-(n, n-диметиламинометил)бензофуран-2-илкарбониламино]этокси}бензамида | |
| JP2019511529A5 (https=) | ||
| EP4442321A3 (en) | Methods of treating sjögren's syndrome using a bruton's tyrosine kinase inhibitor | |
| JP2019528302A5 (https=) | ||
| RU2019132893A (ru) | Комбинированная терапия для лечения рака молочной железы | |
| JP2022525202A5 (https=) | ||
| PH12020552236A1 (en) | Crystal form of compound for inhibiting the activity of cdk4/6 and use thereof | |
| TW200306185A (en) | Combinations comprising EPOTHILONES and anti-metabolites | |
| CN101346137A (zh) | 含有孔布勒塔斯塔坦与抗癌剂的组合物 | |
| JP2016530208A5 (https=) | ||
| JP2017530132A5 (https=) | ||
| CN100553634C (zh) | 用于治疗多发性骨髓瘤的埃坡霉素衍生物 |